Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cadonilimab Plus Anlotinib for Recurrent, Metastasis or Persistent Cervical Cancer

NCT05817214 is registered in ClinicalTrials.gov with Zhongnan Hospital as lead sponsor.

NCT NCT05817214
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05817214 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cadonilimab Plus Anlotinib for Recurrent, Metastasis or Persistent Cervical Cancer
Lead sponsor
Zhongnan Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
February 16, 2023
Completion date
February 28, 2027
Enrollment
35 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer